FDA Cites Long-Term Precedent In Blocking Retail Genetic Screening Plans
This article was originally published in The Gray Sheet
Executive Summary
A particularly public preemptive stance by FDA's in vitro diagnostics oversight office halted Pathway Genomics' plans last week to start selling genetic screening test sample collection kits out of Walgreens stores, but the office's director stresses the move does not signal any changes to its enforcement policy for laboratory-developed tests
You may also be interested in...
Top FDA Officials Warn About Non-Vetted Pharmacogenetic Tests After Latest 23andMe Approval
A day after 23andMe gained US FDA go-ahead for a DTC genetic test service to inform patients about their ability to metabolize medications, the agency issued a safety communication, paired with a joint statement from device- and drug-center heads, warning consumers against trusting genetic tests that have not been vetted by FDA.
Dx Departure: US FDA's Diagnostics Chief Gutierrez Steps Down
Alberto Gutierrez left FDA and government this week in a planned retirement. He was director of the office that oversees pre- and post-market programs for in vitro diagnostics and radiology devices, an office where several holes already exist in top management slots.
Pathway Genomics Remains In FDA Crosshairs For Genetic Testing Service
An untitled letter from FDA targets Pathway Genomics' recent launch of a cancer screening assay that FDA says is being marketed directly to consumers without proper FDA review.